As of 2025-11-05, the Relative Valuation of VistaGen Therapeutics Inc (VTGN) is (20.96) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.07 USD, the upside of VistaGen Therapeutics Inc based on Relative Valuation is -615.0%.
The range of the Relative Valuation is (16.82) - (23.63) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.9x - 16.7x | 14.9x |
| Forward P/E multiples | 11.8x - 18.3x | 14.8x |
| Fair Price | (16.82) - (23.63) | (20.96) |
| Upside | -513.4% - -680.5% | -615.0% |
| Date | P/E |
| 2025-11-03 | -3.00 |
| 2025-10-31 | -2.79 |
| 2025-10-30 | -2.66 |
| 2025-10-29 | -2.81 |
| 2025-10-28 | -2.87 |
| 2025-10-27 | -2.76 |
| 2025-10-24 | -2.88 |
| 2025-10-23 | -2.95 |
| 2025-10-22 | -2.90 |
| 2025-10-21 | -3.00 |
| 2025-10-20 | -3.17 |
| 2025-10-17 | -2.87 |
| 2025-10-16 | -2.87 |
| 2025-10-15 | -2.83 |
| 2025-10-14 | -2.84 |
| 2025-10-13 | -2.77 |
| 2025-10-10 | -2.86 |
| 2025-10-09 | -2.98 |
| 2025-10-08 | -2.85 |
| 2025-10-07 | -2.81 |
| 2025-10-06 | -2.76 |
| 2025-10-03 | -2.59 |
| 2025-10-02 | -2.55 |
| 2025-10-01 | -2.52 |
| 2025-09-30 | -2.52 |
| 2025-09-29 | -2.51 |
| 2025-09-26 | -2.50 |
| 2025-09-25 | -2.39 |
| 2025-09-24 | -2.46 |
| 2025-09-23 | -2.44 |
| 2025-09-22 | -2.36 |
| 2025-09-19 | -2.11 |
| 2025-09-18 | -2.15 |
| 2025-09-17 | -2.05 |
| 2025-09-16 | -2.06 |
| 2025-09-15 | -2.30 |
| 2025-09-12 | -2.40 |
| 2025-09-11 | -2.48 |
| 2025-09-10 | -2.53 |
| 2025-09-09 | -2.56 |
| 2025-09-08 | -2.47 |
| 2025-09-05 | -2.52 |
| 2025-09-04 | -2.56 |
| 2025-09-03 | -2.61 |
| 2025-09-02 | -2.49 |
| 2025-08-29 | -2.37 |
| 2025-08-28 | -2.29 |
| 2025-08-27 | -2.25 |
| 2025-08-26 | -2.20 |
| 2025-08-25 | -2.15 |